# FDA Approves First Drug to Treat Full Range of Narcolepsy Type 1 Symptoms

> fda · REPORTED · 2026-08-05

On August 5, 2026, the FDA approved the first drug indicated to treat the full spectrum of narcolepsy type 1 symptoms, addressing a longstanding gap in care for patients with this rare sleep disorder. This follows FDA's July 2026 oncology approvals including selpercatinib, lutetium Lu 177, and pembrolizumab combinations.

About Jazz Pharmaceuticals: Jazz Pharmaceuticals is a biopharmaceutical company focused on neuroscience and oncology, developing and commercializing therapies for patients with serious diseases including sleep disorders and hematologic cancers.

- Company: Jazz Pharmaceuticals
- Sector: therapeutics
- Primary source: https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-treat-full-range-narcolepsy-type-1-symptoms

---
Source: MedFuel Intel news monitor. Verification tier: REPORTED. Informational only, not investment advice. Corrections: media@medfuelinc.com.